Ignet

Gene Information

Gene symbol: NDN

Gene name: necdin, melanoma antigen (MAGE) family member

HGNC ID: 7675

Synonyms: HsT16328, PWCR

Related Genes

#	Gene Symbol	Number of hits
1	ADIPOQ	1 hits
2	E2F4	1 hits
3	INS	1 hits
4	TRO	1 hits

Related Sentences

#	PMID	Sentence
1	16505226	Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue.
2	16505226	The expression of cell cycle regulatory transcription factors E2F4 and the MAGE protein necdin were similarly altered in all subjects after rosiglitazone treatment.
3	16505226	E2F4 expression was decreased by 10-fold in muscle and 2.5-fold in adipose tissue; necdin was identified in adipose tissue only and increased 1.8-fold after TZD treatment.
4	16505226	While treatment of differentiated adipocytes with rosiglitazone did not alter E2F4 or necdin, expression of both genes was significantly altered during differentiation.
5	16505226	Moreover, necdin overexpression potently inhibited adipocyte differentiation and cell cycle progression.
6	16505226	These data suggest that changes in necdin and E2F4 expression after rosiglitazone exposure in humans are associated with altered adipocyte differentiation and may contribute to improved insulin sensitivity in humans treated with TZDs.
7	16505226	Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue.
8	16505226	The expression of cell cycle regulatory transcription factors E2F4 and the MAGE protein necdin were similarly altered in all subjects after rosiglitazone treatment.
9	16505226	E2F4 expression was decreased by 10-fold in muscle and 2.5-fold in adipose tissue; necdin was identified in adipose tissue only and increased 1.8-fold after TZD treatment.
10	16505226	While treatment of differentiated adipocytes with rosiglitazone did not alter E2F4 or necdin, expression of both genes was significantly altered during differentiation.
11	16505226	Moreover, necdin overexpression potently inhibited adipocyte differentiation and cell cycle progression.
12	16505226	These data suggest that changes in necdin and E2F4 expression after rosiglitazone exposure in humans are associated with altered adipocyte differentiation and may contribute to improved insulin sensitivity in humans treated with TZDs.
13	16505226	Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue.
14	16505226	The expression of cell cycle regulatory transcription factors E2F4 and the MAGE protein necdin were similarly altered in all subjects after rosiglitazone treatment.
15	16505226	E2F4 expression was decreased by 10-fold in muscle and 2.5-fold in adipose tissue; necdin was identified in adipose tissue only and increased 1.8-fold after TZD treatment.
16	16505226	While treatment of differentiated adipocytes with rosiglitazone did not alter E2F4 or necdin, expression of both genes was significantly altered during differentiation.
17	16505226	Moreover, necdin overexpression potently inhibited adipocyte differentiation and cell cycle progression.
18	16505226	These data suggest that changes in necdin and E2F4 expression after rosiglitazone exposure in humans are associated with altered adipocyte differentiation and may contribute to improved insulin sensitivity in humans treated with TZDs.
19	16505226	Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue.
20	16505226	The expression of cell cycle regulatory transcription factors E2F4 and the MAGE protein necdin were similarly altered in all subjects after rosiglitazone treatment.
21	16505226	E2F4 expression was decreased by 10-fold in muscle and 2.5-fold in adipose tissue; necdin was identified in adipose tissue only and increased 1.8-fold after TZD treatment.
22	16505226	While treatment of differentiated adipocytes with rosiglitazone did not alter E2F4 or necdin, expression of both genes was significantly altered during differentiation.
23	16505226	Moreover, necdin overexpression potently inhibited adipocyte differentiation and cell cycle progression.
24	16505226	These data suggest that changes in necdin and E2F4 expression after rosiglitazone exposure in humans are associated with altered adipocyte differentiation and may contribute to improved insulin sensitivity in humans treated with TZDs.
25	16505226	Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue.
26	16505226	The expression of cell cycle regulatory transcription factors E2F4 and the MAGE protein necdin were similarly altered in all subjects after rosiglitazone treatment.
27	16505226	E2F4 expression was decreased by 10-fold in muscle and 2.5-fold in adipose tissue; necdin was identified in adipose tissue only and increased 1.8-fold after TZD treatment.
28	16505226	While treatment of differentiated adipocytes with rosiglitazone did not alter E2F4 or necdin, expression of both genes was significantly altered during differentiation.
29	16505226	Moreover, necdin overexpression potently inhibited adipocyte differentiation and cell cycle progression.
30	16505226	These data suggest that changes in necdin and E2F4 expression after rosiglitazone exposure in humans are associated with altered adipocyte differentiation and may contribute to improved insulin sensitivity in humans treated with TZDs.
31	16505226	Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue.
32	16505226	The expression of cell cycle regulatory transcription factors E2F4 and the MAGE protein necdin were similarly altered in all subjects after rosiglitazone treatment.
33	16505226	E2F4 expression was decreased by 10-fold in muscle and 2.5-fold in adipose tissue; necdin was identified in adipose tissue only and increased 1.8-fold after TZD treatment.
34	16505226	While treatment of differentiated adipocytes with rosiglitazone did not alter E2F4 or necdin, expression of both genes was significantly altered during differentiation.
35	16505226	Moreover, necdin overexpression potently inhibited adipocyte differentiation and cell cycle progression.
36	16505226	These data suggest that changes in necdin and E2F4 expression after rosiglitazone exposure in humans are associated with altered adipocyte differentiation and may contribute to improved insulin sensitivity in humans treated with TZDs.